Stephanie Johnson‐Obaseki
Papers
4
Total Citations
675
H-Index
4
About
Dr. Stephanie Johnson‐Obaseki is a leading head and neck surgical oncologist whose research has fundamentally shaped the debate between surgical and non-surgical treatments for oropharyngeal cancer. Her primary research areas focus on transoral robotic surgery (TORS) and radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC), with a particular emphasis on comparative effectiveness, functional outcomes, and cost-efficiency. Dr. Johnson‐Obaseki is best known as the principal investigator of the landmark ORATOR trial, a phase 2 randomized study that directly compared radiotherapy to TORS with neck dissection. The initial 2019 results, cited over 450 times, provided crucial prospective data on swallowing-related quality of life and survival outcomes, challenging existing treatment paradigms. She subsequently led the 2024 final analysis of the ORATOR trial, offering definitive long-term data on this critical clinical question. Her earlier systematic review on TORS outcomes, with over 130 citations, established a foundational evidence base for the surgical approach. Complementing this clinical work, her cost-effectiveness analysis demonstrated the economic implications of treatment selection. Through these rigorous, high-impact studies, Dr. Johnson‐Obaseki has provided the evidence necessary to guide shared decision-making for patients and clinicians facing this challenging treatment choice.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4